What’s the big deal about Bartolo Colon’s stem cell injections?

17 Comments

There was some moderate-to-serious hand-wringing the other day when it was revealed that Bartolo Colon received an injection of his own stem cells to help repair ligaments.  As David Epstein notes in a very informative article over at SI, however, the hand-wringing is unwarranted.  Colon’s procedure is fairly commonplace and, in its general effect, is no different than microfracture surgery, which no one thinks is a problem.

He likens the response to Colon’s procedure to another procedure — platelet rich plasma therapy — that caused people to freak out a little bit in recent years. In both cases, however, the therapy itself is noncontroversial. The source of the controversy was the doctor at the center of the particular case: Anthony Galea in PRP and Joseph R. Purita in the case of Colon’s stem cell thing.  Galea remains in legal trouble over his alleged use, purchase and transport of HGH. Purita because he admitted that in his non-athlete patients he uses HGH in the stem cell therapy.

Given the level of misinformation and ignorance floating around sports media and among fans when it comes to things like PEDs, it’s not surprising that new-to-us medical procedures lead to raised eyebrows.  But we should all understand that, for the vast majority of us, when we talk about medicine, we really don’t know what the hell we’re talking about.

Rays’ Díaz gets $24 million, three-year deal, avoids arbitration

Getty Images
1 Comment

ST. PETERSBURG, Fla. – Tampa Bay Rays infielder Yandy Díaz agreed to a $24 million, three-year contract on Tuesday that avoided a salary arbitration hearing.

Díaz’s agreement could be worth $36 million over four seasons.

The 31-year old will receive $6 million this season, $8 million in 2024 and $10 million for 2025. The 2026 club is $12 million with no buyout. There is a $1 million assignment bonus that would be payable by receiving team.

Díaz has spent parts of six seasons in the majors with Cleveland (2017-18) and Tampa Bay (2019-22). He has a career average of .278 with 39 home runs and 198 RBIs.

Acquired by the Rays in a three-team trade on Dec. 13, 2018, Díaz hit .296 with nine homers and 57 RBIs in 137 games last season, He career highs with 71 runs, 140 hits, 33 doubles, and 78 walks.

Díaz was the third Rays’ arbitration-eligible player to reach a deal.

Reliever Pete Fairbanks agreed Friday to a $12 million, three-year contract that could be worth up to $24.6 million over four seasons. The 29-year-old right-hander was 0-0 with a 1.13 ERA in 24 appearances last year after beginning the season on the 60-day injured list with a right lat strain.

Left-hander Jeffrey Springs also agreed last week to a $31 million, four-year contract that could be worth $65.75 million over five seasons.

The 30-year-old began last season in the bullpen and transitioned to the starting rotation in May and finished 9-5 with a 2.46 ERA in 33 appearances, including 25 starts.

Tampa Bay remains scheduled for hearings with right-handers Jason Adam and Ryan Thompson, left-hander Colin Poche, and outfielder Harold Ramírez.